ストックスクリーナーアプリを入手
0.1296
6.93%
0.0084
プレマーケット:
.13
0.0004
+0.31%
前日終値:
$0.1212
開ける：
$0.1299
24時間の取引高:
2.34M
Relative Volume:
2.51
時価総額：
$5.57M
収益：
$7.10M
当期純損益:
$-39.43M
株価収益率:
-0.1379
EPS:
-0.94
ネットキャッシュフロー:
$-46.50M
1週間 パフォーマンス:
-1.82%
1か月 パフォーマンス:
-61.50%
6か月 パフォーマンス:
-76.69%
1年 パフォーマンス:
-81.27%
1日の値動き範囲:
$0.1213
$0.135
1週間の範囲:
$0.11
$0.1382
52週間の値動き範囲:
$0.11
$0.87
Spruce Biosciences Inc Stock (SPRB) Company Profile
名前
Spruce Biosciences Inc
セクター
電話
(415) 655-4168
住所
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
SPRB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
0.1296 | 5.57M | 7.10M | -39.43M | -46.50M | -0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-11 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-12-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-03-14 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-03-14 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-03-14 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-14 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-03-14 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-21 | 開始されました | Guggenheim | Buy |
| 2021-12-17 | 開始されました | Oppenheimer | Outperform |
| 2021-12-10 | 開始されました | The Benchmark Company | Speculative Buy |
| 2021-11-16 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-19 | 開始されました | H.C. Wainwright | Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2020-11-03 | 開始されました | Cowen | Outperform |
| 2020-11-03 | 開始されました | Credit Suisse | Outperform |
| 2020-11-03 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-11-03 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Spruce Biosciences Inc (SPRB) 最新ニュース
Monitoring B2gold Corp (BTG) after recent insider movements - knoxdaily.com
TD Cowen reiterates NextDecade Corporation (NEXT) stock to a Buy - knoxdaily.com
Q1 Earnings Forecast for SPRB Issued By Leerink Partnrs - Defense World
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives $2.17 Consensus Target Price from Analysts - Defense World
Spruce Biosciences, Inc. (NASDAQ:SPRB) Q1 2023 Earnings Call Transcript - Insider Monkey
Spruce Biosciences Inc (NASDAQ: SPRB) Slashes -6.82%: What Could Be On The Way Going Forward? - stocksregister.com
Spruce Bio sows the seeds of its new future - Pharmaphorum
Spruce Pivots After Pipeline Failure With BioMarin Tralesinidase Deal - insights.citeline.com
Spruce Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
RBC Cuts Price Target on Spruce Biosciences to $0.50 From $1.50, Keeps Sector Perform, Speculative Risk - marketscreener.com
Spruce Biosciences Announces New Corporate Strategy and Acquisit - GuruFocus
SPRB stock touches 52-week low at $0.18 amid market challenges By Investing.com - Investing.com South Africa
Spruce Biosciences plans BLA for rare disease therapy By Investing.com - Investing.com South Africa
With BioMarin deal, Spruce Biosciences hits reset on rare-disease drugSan Francisco Business Times - The Business Journals
Deal Watch: Oak Hill Picks Up Where Roche Left Off In Angelman Syndrome - insights.citeline.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Spruce Biosciences Acquires Tralesinidase Alfa From BioMarin - marketscreener.com
Crude Oil Moves Lower; Citigroup Posts Upbeat Results - Benzinga
SPRB stock touches 52-week low at $0.18 amid market challenges - Investing.com Canada
Nasdaq Surges 100 Points; Bank of America Earnings Top Views - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Spruce Biosciences (SPRB) Acquires New Therapy for Rare Disease Treatment | SPRB Stock News - GuruFocus
Spruce Biosciences plans BLA for rare disease therapy - Investing.com Australia
SPRUCE BIOSCIENCES, INC. SEC 10-K Report - TradingView
Spruce Biosciences Announces New Corporate Strategy And Acquisition Of Tralesinidase Alfa - MarketScreener
Major Rare Disease Breakthrough: Spruce Bio Secures Promising Treatment for Fatal Childhood Disease - Stock Titan
Layoff Tracker: Opthea Slashes 65% of Staff, Pfizer Cuts 56 - BioSpace
Levi & Korsinsky Reminds Shareholders of an Investigation into Spruce Biosciences, Inc. (SPRB) Regarding Potential Securities Fraud Allegations - ACCESS Newswire
SPRB stock touches 52-week low at $0.26 amid market challenges By Investing.com - Investing.com South Africa
SPRB stock touches 52-week low at $0.26 amid market challenges - Investing.com India
Congenital Adrenal Hyperplasia Treatment Market: Key Trends, - openPR.com
Spruce Biosciences reports delayed annual filing By Investing.com - Investing.com Australia
Spruce Biosciences reports delayed annual filing - Investing.com
Spruce Biosciences Delays Annual Report Filing - TipRanks
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Spruce Biosciences stock hits 52-week low at $0.32 - Investing.com
In-Depth Analysis Of The Global Congenital Adrenal Hyperplasia Market: Key Drivers, Trends, Growth Opportun... - WhaTech
Spruce Biosciences stock hits 52-week low at $0.32 By Investing.com - Investing.com Canada
SPRUCE BIOSCIENCES INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Analysts Set Spruce Biosciences, Inc. (NASDAQ:SPRB) PT at $2.38 - Defense World
SPRB Stock Touches 52-Week Low at $0.34 Amid Steep Decline - Investing.com India
Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Spruce Biosciences (SPRB) to Release Quarterly Earnings on Wednesday - Defense World
Harbour Biomed newco HBM Alpha pens $395M hyperplasia drug deal - BioWorld Online
SPRB stock touches 52-week low at $0.34 amid sharp annual decline - Investing.com
Short Interest in Kingsoft Co. Limited (OTCMKTS:KSFTF) Increases By 79.4% - Defense World
Archer-Daniels-Midland Company (NYSE:ADM) Receives Consensus Rating of “Reduce” from Brokerages - Defense World
Spruce Biosciences Inc (SPRB) 財務データ
収益
当期純利益
現金流量
EPS
1.00%
大文字化:
|
ボリューム (24 時間):